Cell therapy for cytomegalovirus infection

Area of Science:

• Immunology
• Virology
• Hematology

Background:

• Cytomegalovirus (CMV) infection is common but usually benign in healthy individuals.
• In hematopoietic stem cell transplant (HSCT) recipients, uncontrolled CMV can lead to severe complications and mortality.
• Current strategies focus on surveillance and antiviral prophylaxis, aiming to support patients until immune recovery.

Purpose of the Study:

• To review the current management of CMV in HSCT patients.
• To discuss the evolution and advancements in CMV-specific T-cell adoptive therapy.
• To consider the future landscape of CMV treatment in light of new prophylactic agents and cellular therapies.

Main Methods:

• Literature review of CMV management strategies.
• Review of the development of CMV-specific T-cell adoptive therapy, from T-cell clones to third-party Viral-Specific T-cells (VSTs).
• Discussion of expert opinions on the economic viability and patient selection for cellular therapies.

Main Results:

• Adoptive transfer of CMV-specific T-cells has progressed significantly over 25 years.
• The introduction of letermovir prophylaxis is expected to reduce CMV reactivation incidence.
• Clinical trials are crucial for identifying optimal candidates for cellular therapies.

Conclusions:

• The field of CMV management in HSCT is advancing with new prophylactic and therapeutic options.
• Cellular therapies, particularly VSTs, represent a promising avenue for CMV control post-HSCT.
• Future directions emphasize cost-effectiveness and precise patient stratification for cellular therapy interventions.